Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/66867
Tipo de documento
ArtigoDireito Autoral
Acesso restrito
Coleções
Metadata
Mostrar registro completo
ANTI-INFLAMMATORY EFFECT OF METHYL GALLATE ON EXPERIMENTAL ARTHRITIS: INHIBITION OF NEUTROPHIL RECRUITMENT, PRODUCTION OF INFLAMMATORY MEDIATORS, AND ACTIVATION OF MACROPHAGES
fator de necrose alfa
ensaio controlado por placebo
artrite reumatoide
óxido nítrico
estresse oxidativo
duplo cego
tnf alfa
inflamação articular
recrutamento de leucócitos
necrosis factor alpha
placebo controlled trial
rheumatoid arthritis
nitric oxide
oxidative stress
double blind
tnf alpha
articular inflammation
leukocyte recruitment
Autor(es)
Afiliação
Laboratory of Applied Pharmacology Farmanguinhos, Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil / National Institute for Science and Technology on Innovation on Neglected Diseases (INCT/IDN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil
Laboratory of Applied Pharmacology Farmanguinhos, Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil / National Institute for Science and Technology on Innovation on Neglected Diseases (INCT/IDN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil
Laboratory of Applied Pharmacology Farmanguinhos, Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil
Laboratory of Applied Pharmacology Farmanguinhos, Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil / National Institute for Science and Technology on Innovation on Neglected Diseases (INCT/IDN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil
Laboratory of Applied Pharmacology Farmanguinhos, Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil / National Institute for Science and Technology on Innovation on Neglected Diseases (INCT/IDN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil
Laboratory of Applied Pharmacology Farmanguinhos, Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil / National Institute for Science and Technology on Innovation on Neglected Diseases (INCT/IDN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil
Laboratory of Applied Pharmacology Farmanguinhos, Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil / National Institute for Science and Technology on Innovation on Neglected Diseases (INCT/IDN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil
Laboratory of Applied Pharmacology Farmanguinhos, Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil / National Institute for Science and Technology on Innovation on Neglected Diseases (INCT/IDN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil
Fundação Oswaldo Cruz. Centro de Desenvolvimento Tecnológico em Saúde. Instituto Nacional de Ciência e Tecnologia de Inovação em Doenças de Populações Negligenciadas. Rio de Janeiro, RJ, Brasil.
Laboratory of Applied Pharmacology Farmanguinhos, Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil / National Institute for Science and Technology on Innovation on Neglected Diseases (INCT/IDN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil
Laboratory of Applied Pharmacology Farmanguinhos, Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil
Laboratory of Applied Pharmacology Farmanguinhos, Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil / National Institute for Science and Technology on Innovation on Neglected Diseases (INCT/IDN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil
Laboratory of Applied Pharmacology Farmanguinhos, Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil / National Institute for Science and Technology on Innovation on Neglected Diseases (INCT/IDN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil
Laboratory of Applied Pharmacology Farmanguinhos, Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil / National Institute for Science and Technology on Innovation on Neglected Diseases (INCT/IDN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil
Laboratory of Applied Pharmacology Farmanguinhos, Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil / National Institute for Science and Technology on Innovation on Neglected Diseases (INCT/IDN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil
Laboratory of Applied Pharmacology Farmanguinhos, Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil / National Institute for Science and Technology on Innovation on Neglected Diseases (INCT/IDN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil
Fundação Oswaldo Cruz. Centro de Desenvolvimento Tecnológico em Saúde. Instituto Nacional de Ciência e Tecnologia de Inovação em Doenças de Populações Negligenciadas. Rio de Janeiro, RJ, Brasil.
Resumo
O galato de metila (MG) é um ácido fenólico prevalente no reino vegetal, e sua presença em medicamentos fitoterápicos pode estar relacionada aos seus notáveis efeitos biológicos, como suas atividades antioxidantes, antitumorais e antimicrobianas. Embora algumas evidências indiretas sugiram atividade anti-inflamatória para MG, não há estudos demonstrando esse efeito em modelos animais. Aqui, demonstramos que MG (0,7-70 mg/kg) inibiu a artrite experimental induzida por zimosan de maneira dose-dependente. A administração oral de MG (7 mg/kg) atenua a artrite induzida por zimosan, afetando a formação de edema, a migração de leucócitos e a produção de mediadores inflamatórios (IL-1β, IL-6, TNF-α, CXCL-1, LTB4 e PGE2). O pré-tratamento com MG inibiu a quimiotaxia de neutrófilos in vitro induzida por CXCL-1, bem como a adesão dessas células a células endoteliais preparadas com TNF-α. MG também prejudicou macrófagos estimulados por zimosan ao inibir a produção de IL-6 e NO, expressão de COX-2 e iNOS e mobilização de cálcio intracelular. Assim, MG provavelmente apresenta um efeito anti-inflamatório ao atingir múltiplos eventos celulares, como a produção de vários mediadores inflamatórios, bem como ativação e migração de leucócitos.
Resumo em Inglês
Methyl gallate (MG) is a prevalent phenolic acid in the plant kingdom, and its presence in herbal medicines might be related to its remarkable biological effects, such as its antioxidant, antitumor, and antimicrobial activities. Although some indirect evidence suggests anti-inflammatory activity for MG, there are no studies demonstrating this effect in animal models. Herein, we demonstrated that MG (0.7-70 mg/kg) inhibited zymosan-induced experimental arthritis in a dose-dependent manner. The oral administration of MG (7 mg/kg) attenuates arthritis induced by zymosan, affecting edema formation, leukocyte migration, and the production of inflammatory mediators (IL-1β, IL-6, TNF-α, CXCL-1, LTB4, and PGE2). Pretreatment with MG inhibited in vitro neutrophil chemotaxis elicited by CXCL-1, as well as the adhesion of these cells to TNF-α-primed endothelial cells. MG also impaired zymosan-stimulated macrophages by inhibiting IL-6 and NO production, COX-2 and iNOS expression, and intracellular calcium mobilization. Thus, MG is likely to present an anti-inflammatory effect by targeting multiple cellular events such as the production of various inflammatory mediators, as well as leukocyte activation and migration.
Palavras-chave
artrite induzida por zymosanfator de necrose alfa
ensaio controlado por placebo
artrite reumatoide
óxido nítrico
estresse oxidativo
duplo cego
tnf alfa
inflamação articular
recrutamento de leucócitos
Palavras-chave em inglês
zymosan induced arthritisnecrosis factor alpha
placebo controlled trial
rheumatoid arthritis
nitric oxide
oxidative stress
double blind
tnf alpha
articular inflammation
leukocyte recruitment
Compartilhar